01/14/2026 | Press release | Distributed by Public on 01/14/2026 04:57
The European Commission has published the Horizon Europe Work Programmes for 2026-2027, confirming EUR 14 billion in EU investment to support research and innovation across Europe over the next two years. In line with the EUDA mandate (1), we have reviewed the programmes and identified a set of upcoming Horizon Europe calls of relevance to drug-related research and innovation. These calls span multiple parts of the programme, including:
Together, these funding opportunities are relevant to a wide range of stakeholders working on issues relating to drugs, public health, social responses, security and research capacity building.
The Horizon Europe Work Programmes 2026-2027 place a strong emphasis on international collaboration and participation is encouraged from associated and other third countries. All sections of the programmes actively encourage international collaboration, with a particular focus on initiatives involving Africa, the Mediterranean, Latin America and the Caribbean countries and increased collaboration with India and South-East Asian nations. While entities from some third countries may not be automatically eligible for EU funding, their participation may be supported through complementary national funding mechanisms. This approach reflects Horizon Europe's objective of addressing complex societal challenges through transnational and interdisciplinary research and innovation.
To support applicants, the European Commission is organising a set of Cluster 1 and Cluster 3 events:
Follow the publication of calls on the EU Funding & Tenders Portal
For application support, a National Contact Point network is available to provide guidance and assistance in your own language.
Updates will also be shared via the EUDA Drug-related research webpage.